The success of EGFR tyrosine kinase inhibitor (TKIs) have provided a powerful validation for precision cancer medicine because the over-expression and mutations on EGFR plays an important carcinogenic role in a variety of solid tumors such as head and neck, breast, lung, and colorectal cancer, and numerous EGFR inhibitor have been widely used in clinical treatment [24–27]. This evidence concerns the gene EGFR and cancer.